Roche's DAC investment; Big Pharma's lavish CEO bumps [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Some of the biggest news and trends captured in PharmaVoice's newsletter this week. Sign up here to receive the newsletter daily. DAC attack There's a cooler version of ADCs emerging in cancer R&D. Called DACs, or degrader-antibody conjugates, the new modality combines the power of targeted protein degraders with ADCs, and is increasingly driving deals by Big Pharmas. Roche laid down $20 million last week to deepen a partnership with C4 Therapeutics that could eventually be worth up to $1 billion and is centered around DAC development. The company is joining several large pharmas — including Bristol Myers Squibb and Merck & Co. — investing in early-stage DAC research. But not all Big Pharma companies are jumping on the same R&D bandwagons, and instead, many have become more specialized. This week, we looked closer at how pharma giants are leaning into their unique R&D strengths CEO-to-worker ratio growth In 1965, the average CEO of a major U.S. company brought home 21 tim
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Better Pharma Dividend Stock: Novartis vs. Merck [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Better Pharma Dividend Stock: Novartis vs. Merck [Yahoo! Finance]Yahoo! Finance
- UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview [Yahoo! Finance]Yahoo! Finance
- European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV SeasonBusiness Wire
- Harbour BioMed Appoints Dr. Adam Zong as President [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- 4/8/26 - Form DEF
- MRK's page on the SEC website